ArticleNature2025
Designed endocytosis-inducing proteins degrade targets and amplify signals.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed.
- Unlocking the "undruggable": current landscape and emerging frontiers in lysosomal receptor-mediated protein degradation.Drug delivery · 2026Review
- Engineered CTLA-4 targeting chimeras for targeted protein degradation and immune synapse reprogramming.bioRxiv : the preprint server for biology · 2026Article
- Article
- The cellular landscape of druggable RNA-binding proteins.Nature reviews. Drug discovery · 2026Review
- Targeted Lysosomal Degradation of Extracellular and Membrane Proteins: From Receptor Hijacking to Programmable Endolysosomal Routing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Nanotechnology-Enabled Targeted Protein Degradation: Strategies, Opportunities, and Challenges.Small methods · 2026Review
- Multiparatopic antibodies overcome tyrosine kinase inhibitor resistance by inducing lysosomal degradation of EGFR mutants.Oncogene · 2026Article
- De Novo-Designed Bifunctional Proteins for Targeted Protein Degradation.Journal of the American Chemical Society · 2026Article
- Artificial intelligence empowers targeted protein degradation: Core technological innovations, multi-scenario applications, and translational prospects.Smart molecules : open access · 2026Review
- A Plug-and-Play Platform for Customizing Multivalent Degraders and Degrader-Drug Conjugates.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A destination-driven framework for nanoparticle-enabled targeted protein degradation.Acta pharmaceutica Sinica. B · 2026Review
- Mapping and engineering the human cell-cell interactome.Nature biotechnology · 2026Review
- Article
- Functionalized Fluorescent Nanodiamonds Reveal Therapeutic Protein Clearance Through ENDOTAC Linked to AUTOTAC.Advanced healthcare materials · 2026Article
- Endosomes as central hubs of interorganellar communication and cellular homeostasis.Protein & cell · 2026Review
- Protein design and RNA design: Perspectives.Quantitative biology (Beijing, China) · 2026Article
- "Artificial platelet injection system": a plug-and-play platelet-based lysosome-targeting chimera for targeted protein degradation.Bioactive materials · 2026Article
- Sensing and Reprogramming Surface Receptor Activation With Synthetic Transcriptional Circuits.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Designed Minibinders Rewire Receptor Signaling to Enable Functional Human Myogenic Reprogramming.bioRxiv : the preprint server for biology · 2026Article
- Peptide-Based PROTACs: Transitioning from Static Paradigm to a Dynamic Landscape within Targeted Protein Degradation.Bioconjugate chemistry · 2026Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors.
Buwei Huang *Department of Biochemistry, University of Washington, Seattle, WA, USA.
Mohamad Abedi *Department of Biochemistry, University of Washington, Seattle, WA, USA.
Green Ahn *Department of Chemistry, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-3086-4849
Brian Coventry *Department of Biochemistry, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-6910-6255
Isaac SappingtonDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Cong TangInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.ORCID http://orcid.org/0000-0003-1661-6793
Rong WangDepartment of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0001-7342-5278
Thomas SchlichthaerleDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Jason Z ZhangDepartment of Biochemistry, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-0091-6273
Yujia WangInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Inna GoreshnikDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Ching Wen ChiuInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Adam Chazin-GrayDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Sidney ChanInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Stacey GerbenInstitute for Protein Design, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-0313-6248
Analisa MurrayInstitute for Protein Design, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-1560-6673
Shunzhi WangDepartment of Biochemistry, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-5033-7478
Jason O'NeillNovo Nordisk, Måløv, Denmark.
Li YiNovo Nordisk, Måløv, Denmark.
Ronald YehNovo Nordisk, Måløv, Denmark.
Ayesha MisquithNovo Nordisk, Måløv, Denmark.
Anitra WolfNovo Nordisk, Måløv, Denmark.
Luke M TomasovicDepartments of Biomedical Engineering and Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-1459-3252
Dan I PiranerDepartment of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA.
Maria J Duran GonzalezDepartment of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA.
Nathaniel R BennettDepartment of Biochemistry, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-8590-1454
Preetham VenkateshDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Maggie AhlrichsInstitute for Protein Design, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-4793-3890
Craig DobbinsInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Wei YangDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Xinru WangDepartment of Biochemistry, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-5994-707X
Danny D SahtoeHubrecht Institute, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0001-9095-0744
Dionne VafeadosInstitute for Protein Design, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-2560-8907
Rubul MoutHarvard Medical School, Harvard University, Boston, MA, USA.
Shirin ShivaeiDivision of Biology and Bioengineering, California Institute of Technology, Pasadena, CA, USA.
Longxing CaoSchool of Life Sciences, Westlake University, Hangzhou, China.
Lauren CarterInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Lance StewartInstitute for Protein Design, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-4264-5125
Jamie B SpanglerNovo Nordisk, Måløv, Denmark.
Kole T RoybalDepartment of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-3030-7954
Per Jr GreisenNovo Nordisk, Måløv, Denmark.
Xiaochun LiDepartment of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0002-0177-0803
Gonçalo J L BernardesInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.ORCID http://orcid.org/0000-0001-6594-8917
Carolyn R BertozziDepartment of Chemistry, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-4482-2754
David BakerDepartment of Biochemistry, University of Washington, Seattle, WA, USA. dabaker@uw.edu.ORCID http://orcid.org/0000-0001-7896-6217
Funding
MOLECULAR AND CELLULAR IMMUNOLOGYT32AI007334 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CYSTER, JASON G · 1988 to 2023
$11.0MMETABOLIC OLIGOSACCHARIDE ENGINEERINGR01GM058867 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI Carolyn Bertozzi · 1999 to 2026
$5.6MMetabolic Engineering with Bioorthogonal Chemical ReportersR37GM058867 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI BERTOZZI, CAROLYN · 2009 to 2018
$4.7MDe Novo Design of Minibinder Antagonists for COVID-19 and Future PandemicsR01AI160052 · NIAID · UNIVERSITY OF WASHINGTON · PI BAKER, DAVID, FULLER, DEBORAH H. · 2021 to 2025
$3.5MDesigned Vehicles for Blood Brain Barrier TraversalR01AG063845 · NIA · UNIVERSITY OF WASHINGTON · PI BAKER, DAVID · 2019 to 2023
$2.5MDesign of de novo interleukin mimics for targeted immunotherapyR01CA240339 · NCI · UNIVERSITY OF WASHINGTON · PI BAKER, DAVID · 2019 to 2023
$2.1MNCI NIH HHS R01 CA240339NIAID NIH HHS R01 AI160052NIAID NIH HHS T32 AI007334NIA NIH HHS R01 AG063845NIGMS NIH HHS R01 GM058867NIGMS NIH HHS R37 GM058867
Abstract
Endocytosis and lysosomal trafficking of cell surface receptors can be triggered by endogenous ligands. Therapeutic approaches such as lysosome-targeting chimaeras
Indexed as
EndocytosisProtein EngineeringProteolysisSignal TransductionAdaptor Proteins, Vesicular TransportAnimalsAsialoglycoprotein ReceptorFemaleHumansLigandsLysosomesMiceReceptor, IGF Type 2Receptors, TransferrinRecombinant Fusion ProteinsSortilinAdaptor Proteins, Vesicular TransportAsialoglycoprotein ReceptorLigandsReceptor, IGF Type 2Receptors, TransferrinRecombinant Fusion ProteinsSortilin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.